首页> 外文期刊>Retina >Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation.
【24h】

Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation.

机译:长期使用华法林钠(Coumadin)进行抗凝治疗的患者的视网膜中央静脉阻塞。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To describe the clinical features of persons who developed central retinal vein occlusion (CVO) while being treated with Coumadin for chronic anticoagulation. METHODS: In a retrospective, comparative, noninterventional case series of patients diagnosed with CVO while being treated with Coumadin as a systemic anticoagulant, visual and anatomical outcomes were compared with those for a cohort of patients diagnosed with CVO who were not treated with any systemic anticoagulation. RESULTS: Fourteen eyes of 14 patients treated with Coumadin were identified. At presentation, the median international normalization ratio (INR) was 2.20 (range, 1.3-5.0). Eight patients (57%) had a therapeutic INR at the time of CVO. Their visual acuity and perfusion status were similar to those of patients with subtherapeutic INR. At the last follow-up (median, 16 months), visual acuity and perfusion status of the group of 14 eyes were similar to baseline findings (P = 0.62). Clinical features and outcomes were similar to those for a cohort of patients with CVO who were not being treated with systemic anticoagulation. CONCLUSION: CVO can occur in patients being treated with Coumadin for systemic anticoagulation. Final visual acuity and perfusion status were similar to those in a cohort of patients with CVO who were not treated with Coumadin. Although visual acuity is unaffected, ensuring that the INR for these patients remains in the therapeutic range may be important to help prevent secondary systemic thrombotic and embolic disease.
机译:目的:描述在使用香豆素进行慢性抗凝治疗的同时发生视网膜中央静脉阻塞(CVO)的患者的临床特征。方法:在一项回顾性,非介入性,非介入性病例系列中,将经香豆素作为全身抗凝剂治疗的CVO患者的视觉和解剖结果与未经任何全身抗凝治疗的CVO患者的视觉和解剖学结果进行了比较。结果:鉴定出14名接受香豆素治疗的患者的14只眼。在介绍时,中位数国际标准化比率(INR)为2.20(范围为1.3-5.0)。 CVO时有八名患者(57%)具有治疗性INR。他们的视敏度和灌注状态与亚治疗性INR患者相似。在最后一次随访(中位数为16个月)时,这组14只眼睛的视敏度和灌注状态与基线发现相似(P = 0.62)。临床特征和结局与未接受全身抗凝治疗的一组CVO患者相似。结论:接受香豆素进行全身抗凝治疗的患者可能发生CVO。最终的视敏度和灌注状态与未接受香豆素治疗的一组CVO患者相似。尽管视力不受影响,但确保这些患者的INR保持在治疗范围内可能对帮助预防继发性系统性血栓性和栓塞性疾病很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号